GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Price-to-Free-Cash-Flow

NEVPF (Abliva AB) Price-to-Free-Cash-Flow : N/A (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Price-to-Free-Cash-Flow?

As of today (2024-12-13), Abliva AB's share price is $0.01. Abliva AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.01. Hence, Abliva AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Abliva AB's Price-to-Free-Cash-Flow or its related term are showing as below:

NEVPF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.545
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Abliva AB's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 67.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 50.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 32.70% per year.

During the past 13 years, Abliva AB's highest 3-Year average Free Cash Flow per Share Growth Rate was 67.80% per year. The lowest was -90.50% per year. And the median was 5.80% per year.


Abliva AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for Abliva AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Price-to-Free-Cash-Flow Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abliva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abliva AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Abliva AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abliva AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Abliva AB's Price-to-Free-Cash-Flow falls into.



Abliva AB Price-to-Free-Cash-Flow Calculation

Abliva AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.01/-0.006
=N/A

Abliva AB's Share Price of today is $0.01.
Abliva AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Abliva AB  (OTCPK:NEVPF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Abliva AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Abliva AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.